Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators

American Journal of Psychiatry

Volumn 170, Issue 3, 2013, Pages 265-274

  Vancampfort, Davy ^a   Vansteelandt, Kristof ^a   Correll, Christoph U ^a   Mitchell, Alex J ^a   De Herdt, Amber ^a   Sienaert, Pascal ^a   Probst, Michel ^a   De Hert, Marc ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; AUSTRALIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; METABOLIC DISORDER; METABOLIC SYNDROME X; NEW ZEALAND; NORTH AMERICA; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; VULNERABLE POPULATION;

EID: 84874776563     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12050620     Document Type: Review

References (40)

1. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ: Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009;11:657-662
2. Osby U, Brandt L, Correia N, Ekbom A, Sparén P: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-850 (Pubitemid 32979302)
3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-1132
4. Expert Panel on Detection and Evaluation of High Blood Cholesterol in Adults: Executive summary of the third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752 (Pubitemid 41532612)
6. Alberti KG, Zimmet P, Shaw P: The metabolic syndrome: a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-480
7. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645
8. Taylor V, MacQueen G: Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006;67:1034-1041 (Pubitemid 44230873)
9. Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC: Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007;9:443-452 (Pubitemid 47202506)
10. Correll CU, Frederickson AM, Kane JM, Manu P: Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788-797
11. Mitchell AJ, Malone D, Doebbeling CC: Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009;194:491-499
12. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S: Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77
13. Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF: Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans, and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005;48:649-656 (Pubitemid 40591219)
14. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359 (Pubitemid 34251969)
15. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-436 (Pubitemid 36241019)
16. McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, Kucyi A, Soczynska JK, Woldeyohannes HO, Lachowski A, Kim B, Nathanson J, Alsuwaidan M, Taylor VH: Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010;126:366-387
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009;6:e1000097
18. Egger M, Davey Smith G, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
19. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101
20. Lipsey MW, Wilson DB: Practical meta-analysis. Thousand Oaks, Calif, Sage, 2001
21. Hedges LV, Olkin I: Statistical models for meta-analysis. New York, Academic Press, 1985
22. Hwang LC, Bai CH, Chen CJ: Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006;105:626-635
23. Correll CU, Lencz T, Malhotra AK: Antipsychotic drugs and obesity. Trends Mol Med 2011;17:97-107
24. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-126
25. North BJ, Sinclair DA: The intersection between aging and cardiovascular disease. Circ Res 2012;110:1097-1108
26. Cipriani A, Rendell JM, Geddes J: Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2009;1:CD004367
27. Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F: Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011;12:e32-e43
28. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR: Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-728
29. Correll CU, Sheridan EM, Del Bello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12:116-141
30. Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. Schizophr Bull (Epub ahead of print, Dec. 29, 2011)
31. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J, Keller M: Long-term symptomatic status of bipolar I vs bipolar II disorders. Int J Neuropsychopharmacol 2003;6:127-137 (Pubitemid 36850965)
32. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB: Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35:1171-1180
33. Garcia-Portilla MP, Saiz PA, Benabarre A, Florez G, Bascaran MT, Díaz EM, Bousoño M, Bobes J: Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scand 2010;121:437-445
34. McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 2012;24:69-81
35. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, Beaulieu S, Yatham LN, Berk M; International Society for Bipolar Disorders: The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009;11:559-595
36. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-424
37. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, De Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J: Advantages and disadvantages of combination treatment with antipsychotics: ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-532
38. Brooks JO 3rd, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME: Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 2011;72:240-247
39. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-542
40. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-147